Blockade of neurokinin3 receptors antagonizes drug-induced population response and depolarization block of midbrain dopamine neurons in guinea pigs

Synapse

Volumn 33, Issue 1, 1999, Pages 71-79

  Gueudet, Christiane ^a   Santucci, Vincent ^a   Soubrié, Philippe ^a   Le Fur, Gérard ^a  

^a SANOFI   (France)

Author keywords

A9 A10 neurons; Extracellular recording; Haloperidol; SR142801; Tachykinins

Indexed keywords

2 [5 (2,6 DIMETHOXYPHENYL) 1 [4 [N (3 DIMETHYLAMINOPROPYL) N METHYLCARBAMOYL] 2 ISOPROPYLPHENYL] 1H PYRAZOL 3 YLCARBONYLAMINO]ADAMANTANE 2 CARBOXYLIC ACID; APOMORPHINE; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ 3 RECEPTOR; NEUROKININ 3 RECEPTOR ANTAGONIST; NEUROKININ B; NEUROTENSIN RECEPTOR ANTAGONIST; OSANETANT; SPIPERONE; [2 METHOXY 5 (1 TETRAZOLYL)BENZYL](2 PHENYL 3 PIPERIDINYL)AMINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; PIPERIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CELL POPULATION; CONTROLLED STUDY; DEPOLARIZATION; DOPAMINERGIC NERVE CELL; GUINEA PIG; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MESENCEPHALON; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BLOCKING; SINGLE UNIT ACTIVITY; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM; ANIMAL; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; ELECTROPHYSIOLOGY; METABOLISM; NERVE CELL; PHYSIOLOGY;

ANIMALS; DOPAMINE; DOPAMINE ANTAGONISTS; ELECTROPHYSIOLOGY; GUINEA PIGS; HALOPERIDOL; MALE; MESENCEPHALON; NEURONS; PIPERIDINES; RECEPTORS, NEUROKININ-3;

EID: 0033153772     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199907)33:1<71::AID-SYN7>3.0.CO;2-2     Document Type: Article

References (59)

1. 3 receptor stimulation in gerbil mesencephalic cell cultures. Eur J Neurosci 8:801-808.
2. Azzi M, Gully D, Heaulme M, Bérod A, Pélaprat D, Kitabgi P, Boigegrain R, Maffrand J-P, Le Fur G, Rostène W. 1994. Neurotensin receptor interaction with dopaminergic systems in the guinea-pig brain shown by neurotensin receptor antagonists. Eur J Pharmacol 255:167-174.
3. Bannon MJ, Whitty CJ. 1995. Neurokinin receptor gene expression in substantia nigra: localization, regulation and potential physiological significance. Can J Physiol Pharmacol 73:866-870.
4. Bannon MJ, Lee JM, Giraud P, Young A, Affolter HU, Bonner TI. 1986. Dopamine antagonist haloperidol decreases substance P, substance K, and preprotachykinin mRNAs in rat striatonigral neurons. J Biol Chem 261:6640-6642.
5. Bannon MJ, Brownschidle LA, Tian Y, Whitty CJ, Poosch MS, D'sa C, Moody CA. 1995. Neurokinin-3 receptors modulate dopamine cell function and alter the effects of 6-hydroxydopamine. Brain Res 695:19-24.
6. Bunney BS, Grace AA. 1978. Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci 23:1715-1728.
7. Bunney BS, Walters JR, Roth RH, Aghajanian GK. 1973. Dopaminergic neurons: effects of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185:560-571.
8. Bunney BS, Chiodo LA, Grace AA. 1991. Midbrain dopamine system electrophysiological functioning: a review and new hypothesis. Synapse 9:79-94.
9. 3): a double immunocytochemical study in the rat. Brain Res 780:150-154.
10. Chiodo LA. 1988. Dopamine-containing neurons in the mammalian central nervous system: electrophysiology and pharmacology. Neurosci Biobehav Rev 12:49-91.
11. Chiodo LA, Bunney BS. 1983. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3:1607-1619.
12. Chiodo LA, Bunney BS. 1985. Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 5:2539-2544.
13. Dam T-V, Quirion R. 1994. Comparative distribution of receptor types in the mammalian brain. In: Buck SH, editor. The tachykinin receptors. Totowa NJ: Humana Press. p 101-123.
14. 3H]senktide. Brain Res 506:175-179.
15. 3 receptor. Life Sci 56:27-32.
16. 2 receptor antagonist. Neuropeptides 31:449-458.
17. Furmidge LJ, Duggan AW, Arbuthnott GW. 1995. In vivo detection of immunoreactive neurokinin A release within rat substantia nigra and its dependency on a dopaminergic input. Brain Res 679:241-248.
18. Gao DM, Hoffman D, Benabid AL. 1996. Simultaneous recording of spontaneous activities and nociceptive responses from neurons in the pars compacta of substantia nigra and in the lateral habenula. Eur J Neurosci 8:1474-1478.
19. Grace AA. 1992. The depolarization block hypothesis of neuroleptic action: implications for the etiology and treatment of schizophrenia. J Neural Transm 36:91-131.
20. Grace AA, Bunney BS. 1983. Intracellular and extracellular electrophysiology of nigral dopaminergic neurones. I. Identification and characterization. Neuroscience 10:301-315.
21. Grace AA, Bunney BS. 1986. Induction of depolarization block in midbrain dopamine neurons by repeated administration of haloperidol: analysis using in vivo intracellular recording. J Pharmacol Exp Ther 238:1092-1100.
22. Graybiel AM. 1990. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 13:244-254.
23. 3H]senktide. Br J Pharmacol 116:253P.
24. Gully D, Canton M, Boigegrain R, Jeanjean F, Molimard J-C, Poncelet M, Gueudet C, Heaulme M, Leyris R, Brouard A, Pelaprat D, Labbé-Jullié C, Mazella J, Soubrié P, Maffrand J-P, Rostène W, Kitabgi P, Le Fur G. 1993. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci USA 90:65-69.
25. Gully D, Labeeuw B, Boigegrain R, Oury-Donat F, Bachy A, Poncelet M, Steinberg R, Suaud-Chagny MF, Santucci V, Vita N, Pecceu F, Labbe-Jullié C, Kitabgi P, Soubrié P, Le Fur G, Maffrand JP. 1997. Biochemical and pharmacological activities of SR 142948, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther 280:802-812.
26. Hollerman JR, Grace AA. 1992. Subthalamic nucleus cell firing in the 6-OHDA-treated rat: basal activity and response to haloperidol. Brain Res 590:291-299.
27. Hong JS, Tilson HA, Yoshikawa K. 1983. Effects of lithium and haloperidol administration on the rat brain levels of substance P. J Pharmacol Exp Ther 224:590.
28. Humpel C, Knaus GA, Auer B, Knaus H-G, Haring C, Theodorsson E, Saria A. 1990. Effects of haloperidol and clozapine on preprotachykinin-A messenger RNA, tachykinin tissue levels, release and neurokinin-1 receptors in the striato-nigral system. Synapse 6:1-9.
29. Kalivas PW. 1993. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Rev 18:75-113.
30. Keegan KD, Woodruff GN, Pinnock RD. 1992. The selective NK3 receptor agonist senktide excites a subpopulation of dopamine-sensitive neurones in the rat substantia nigra pars compacta in vitro. Br J Pharmacol 105:3-5.
31. Kondo Y, Iwatsubo K. 1980. Diminished responses of nigral dopaminergic neurons to haloperidol and morphine following lesions of the striatum. Brain Res 181:237-240.
32. Marco N, Thirion A, Mons G, Bougault I, Le Fur G, Soubrié P, Steinberg R. 1998. Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig. Neuropeptides 32:481-488.
33. Marksteiner J, Saria A, Krause JE. 1992a. Comparative distribution of neurokinin B-, substance P- and enkephalin-like immunoreactivities and neurokinin B messenger RNA in the basal forebrain of the rat: evidence for neurochemical compartmentation. Neuroscience 51:107-120.
34. Marksteiner J, Saria A, Miller CH, Krause JE. 1992b. Differential increase of neurokinin B- and enkephalin-like immunoreactivities and their mRNAs after chronic haloperidol treatment in the rat. Neurosci Lett 148:55-59.
35. Marksteiner J, Saria A, Miller CH, Krause JE. 1993. Increased synthesis of neurokinin B and enkephalin after chronic haloperidol treatment. Regul Pept 46:349-351.
36. Merchenthaler I, Maderdrut JL, O'Harte F, Conlon JM. 1992. Localization of neurokinin B in the central nervous system of the rat. Peptides 13:815-829.
37. 2 receptor antagonist SR 48968 on midbrain dopamine neurons in the rat: an in vivo extracellular single cell study. Synapse 25:196-204.
38. Murase S, Grenhoff J, Chouvet G, Gonon FG, Svensson TH. 1993. Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neurosci Lett 157:53-56.
39. Nalivaiko E, Michaud J-C, Soubrié P, Le Fur G, Feltz P. 1997. Tachykinin neurokinin-1 and neurokinin-3 receptor-mediated responses in guinea-pig substantia nigra: an in vitro electrophysiological study. Neuroscience 78:745-757.
40. 1 receptor antagonist, in the trigeminovascular system. Regul Pept 68:23-29.
41. Poncelet M, Gueudet C, Emonds-Alt X, Brelière J-C, Le Fur G, Soubrié P. 1993, Turning behavior induced in mice by a neurokinin A receptor agonist: stereoselective blockade by SR 48968, a non-peptide receptor antagonist. Neurosci Lett 149:40-42.
42. Pucak ML, Grace AA. 1994. Regulation of substantia nigra dopamine neurons. Crit Rev Neurobiol 9:67-89.
43. Radke JM, MacLennan AJ, Vincent SR, Fibiger HC. 1988. Comparison between short- and long-term haloperidol administration on somatostatin and substance P concentrations in the rat brain. Brain Res 445:55-60.
44. Rapisarda C, Bacchelli B. 1977. The brain of the guinea pig in stereotaxic coordinates. Arch Sci Biol 61:1-37.
45. 3H]senktide. Neuropeptides 18:107-114.
46. Rossetti Z, Marcangione C, Wise RA. 1998. Increase in extracellular glutamate and expression of fos-like immunoreactivity in the ventral tegmental area in response to electrical stimulation of the prefrontal cortex. J Neurochem 70:1503-1512.
47. 2 receptor antagonist SR48968 inhibits thalamic responses evoked by thermal but not mechanical nociception. Eur J Pharmacol 237:143-146.
48. Santucci V, Gueudet C, Steinberg R, Le Fur G, Soubrié P. 1997. Involvement of cortical neurotensin in the regulation of rat mesocortico-limbic dopamine neurons: evidence from changes in the number of spontaneously active A10 cells after neurotensin receptor blockade. Synapse 26:370-380.
49. Seabrook GR, Bowery BJ, Hill RG. 1995. Pharmacology of tachykinin receptors on neurones in the ventral tegmental area of rat brain slices. Eur J Pharmacol 273:113-119.
50. Shughrue PJ, Lane MV, Merchenthaler I. 1996. In situ hybridization analysis of the distribution of neurokinin-3 mRNA in the rat central nervous system. J Comp Neurol 372:395-414.
51. Steinberg R, Marco N, Voutsinos B, Bensaid N, Rodier D, Souilhac J, Alonso R, Oury-Donat F, Le Fur G, Soubrié P. 1998. Expression and presence of septal neurokinin-2 receptors controlling hippocampal acetylcholine release during sensory stimulation in rat. Eur J Neurosci 10:2337-2345.
52. Stoessl AJ. 1994. Localization of striatal and nigral tachykinin receptors in the rat. Brain Res 646:13-18.
53. 3H]senktide. Brain Res 534:1-7.
54. Stoessl AJ, Szczutkowski E, Glenn B, Watson I. 1991. Behavioural effects of selective tachykinin agonists in midbrain dopamine regions. Brain Res 565:254-262.
55. Tsuchida K, Shigemoto R, Yokota Y, Nakanishi S. 1990. Tissue distribution and quantitation of the mRNAs for three tachykinin receptors. Eur J Biochem 193:751-757.
56. Tung CS, Grenhoff J, Svensson TH. 1991. Kynurenate blocks the acute effects of haloperidol on midbrain dopamine neurons recorded in vivo. J Neural Transm (Gen Sect) 84:53-64.
57. White FJ, Wang RY. 1983. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054-1057.
58. Whitty CJ, Walker PD, Goebel DJ, Poosch MS, Bannon MJ. 1995. Quantitation, cellular localization and regulation of neurokinin receptor gene expression within the rat substantia nigra. Neuroscience 64:419-425.
59. Yung WH, Haussler MA, Jack JJB. 1991. Electrophysiology of dopaminergic and non-dopaminergic neurones of the guinea-pig substantia nigra pars compacta in vitro. J Physiol 436:643-667.